CHK1 Cancer Research Results

CHK1, Checkpoint Kinase 1: Click to Expand ⟱
Source:
Type:
A protein that plays a crucial role in the DNA damage response pathway. It is involved in the repair of DNA damage and the maintenance of genome stability.
CHK1 acts as a tumor suppressor by preventing the accumulation of DNA damage and maintaining genome stability. Loss of CHK1 function can lead to increased genetic instability and a higher risk of cancer.
-CHK1 is often overexpressed in various types of cancer, including breast, colorectal, lung, and ovarian cancer. Overexpression of CHK1 can contribute to the development of resistance to chemotherapy and radiation therapy.
-CHK1 expression is often higher in tumor cells compared to normal cells. This tumor-specific expression makes CHK1 a potential target for cancer therapy.
Scientific Papers found: Click to Expand⟱
251- AL,    Inhibition of allicin in Eca109 and EC9706 cells via G2/M phase arrest and mitochondrial apoptosis pathway
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
Apoptosis↑, P53↑, P21↑, CHK1↑, CycB/CCNB1↓, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑,
310- Api,    Apigenin inhibits renal cell carcinoma cell proliferation
- vitro+vivo, RCC, ACHN - in-vitro, RCC, 786-O - in-vitro, RCC, Caki-1 - in-vitro, RCC, HK-2
TumCCA↑, p‑ATM↑, p‑CHK1↑, p‑CDC25↑, p‑cDC2↑, P53↑, BAX↑, Casp9↑, Casp3↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
5808- CPT,    Repair of Topoisomerase I-Mediated DNA Damage
- Review, Var, NA
TOP1↓, AntiCan↑, Dose?, CHK1↑, Chk2↑,
1655- FA,    Ferulic acid inhibiting colon cancer cells at different Duke’s stages
- in-vitro, Colon, SW480 - in-vitro, Colon, Caco-2 - in-vitro, Colon, HCT116
TumCP↓, TumCMig↓, TumCCA↑, Apoptosis↑, ATM↑, Chk2↑, ATR↑, CHK1↑, CK2↓, cycA1/CCNA1↑, CDK4↓, CDK6↓, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
924- RES,    Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells
- in-vitro, OS, U2OS - in-vitro, Lung, A549
TumCCA↑, ROS↑, γH2AX↑, ATM↑, p‑CHK1↑, cellSen↑, CXCR2↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   NRF2↑, 1,   ROS↑, 2,   mt-ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   CDC25↓, 1,   p‑CDC25↑, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   PCK1↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 3,   Bcl-2↓, 1,   Casp↑, 1,   Casp3↑, 2,   Casp9↑, 2,   Chk2↑, 3,   p‑Chk2↑, 1,   CK2↓, 1,   Cyt‑c↑, 2,   Diablo↑, 1,   DR5↑, 1,   Fas↑, 1,   Ferroptosis↑, 1,   IAP2↓, 1,   MAPK↓, 1,   oncosis↑, 1,   p27↑, 1,   p‑p38↓, 1,   survivin↓, 2,  

Transcription & Epigenetics ⓘ

p‑H3↓, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3s↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

ATM↑, 3,   p‑ATM↑, 2,   ATR↑, 1,   p‑ATR↑, 1,   CHK1↑, 4,   p‑CHK1↑, 3,   DNAdam↑, 1,   HR↓, 1,   p16↑, 1,   P53↑, 3,   cl‑PARP↑, 1,   PCNA↓, 1,   RAD51↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 2,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 1,   cycE1↓, 1,   P21↑, 2,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State ⓘ

p‑cDC2↑, 1,   cMET↓, 1,   ERK↓, 1,   GSK‐3β↑, 1,   mTOR↓, 1,   mTORC1↓, 1,   mTORC2↓, 1,   PI3K↓, 1,   RAS↓, 1,   STAT3↓, 1,   TOP1↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Ca+2↑, 1,   CDK4/6↓, 1,   E-cadherin↑, 1,   ITGB1↑, 1,   Ki-67↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP7↓, 1,   MMPs↓, 1,   NCAM↑, 1,   Rho↓, 1,   TGF-β↓, 1,   TIMP2↑, 1,   TumCMig↓, 1,   TumCP↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 1,   KDR/FLK-1↓, 1,   NO↓, 1,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

cellSen↑, 1,   CXCR2↑, 1,   IL1↓, 1,   IL6↓, 1,   JAK1↓, 1,   MIP2↓, 1,   NF-kB↓, 2,   PGE2↓, 1,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose?, 1,   Dose↝, 1,   Half-Life↓, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   RenoP↑, 1,  
Total Targets: 115

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: CHK1, Checkpoint Kinase 1
1 Allicin (mainly Garlic)
1 Apigenin (mainly Parsley)
1 Artemisinin
1 Camptothecin
1 Ferulic acid
1 Fisetin
1 Resveratrol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:594  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page